Adegramotide

Adegramotide
Legal status
Legal status
  • experimental
Identifiers
  • L-tryptophyl-L-alanyl-L-prolyl-L-valyl-L-leucyl-L-alpha-aspartyl-L-phenylalanyl-L-alanyl-L-prolyl-L-prolyl-glycyl-L-alanyl-L-seryl-L-alanyl-L-tyrosyl-glycyl-L-seryl-L-leucine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC87H123N19O24
Molar mass1819.050 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](C)NC(=O)[C@H](CC6=CNC7=CC=CC=C76)N
  • InChI=InChI=1S/C87H123N19O24/c1-44(2)33-58(100-83(125)71(46(5)6)103-82(124)66-24-17-30-104(66)84(126)49(9)94-74(116)56(88)37-53-39-89-57-22-15-14-21-55(53)57)77(119)99-61(38-70(112)113)78(120)98-60(35-51-19-12-11-13-20-51)76(118)95-50(10)85(127)106-32-18-25-67(106)86(128)105-31-16-23-65(105)81(123)91-40-68(110)92-47(7)72(114)102-64(43-108)79(121)93-48(8)73(115)97-59(36-52-26-28-54(109)29-27-52)75(117)90-41-69(111)96-63(42-107)80(122)101-62(87(129)130)34-45(3)4/h11-15,19-22,26-29,39,44-50,56,58-67,71,89,107-109H,16-18,23-25,30-38,40-43,88H2,1-10H3,(H,90,117)(H,91,123)(H,92,110)(H,93,121)(H,94,116)(H,95,118)(H,96,111)(H,97,115)(H,98,120)(H,99,119)(H,100,125)(H,101,122)(H,102,114)(H,103,124)(H,112,113)(H,129,130)/t47-,48-,49-,50-,56-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,71-/m0/s1
  • Key:QMUKFZMAYHSADK-MZDDNWLQSA-N

Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials.

As of 14 December 2021, phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab.

The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of 13 August 2024, is still continuing as planned.

References

  1. ↑ Spira A, Hansen AR, Harb WA, Curtis KK, Koga-Yamakawa E, Origuchi M, Li Z, Ertik B, Shaib WL (July 2021). "Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies". Targeted Oncology. 16 (4): 461–469. doi:10.1007/s11523-021-00813-6. PMC 8266707. PMID 33939067.
  2. ↑ Boston Biomedical (11 May 2017). "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy". ClinicalTrials.gov. U.S. National Library of Medicine.
  3. ↑ Suginobe; et al. "Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors". pubchem.ncbi.nlm.nih.gov.
  4. 1 2 Sumitomo Dainippon Pharma Oncology Inc. "Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma". www.prnewswire.com. Archived from the original on 2024-08-13. Retrieved 2024-08-13.
  5. ↑ "Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates | Sumitomo Pharma". www.sumitomo-pharma.com. Archived from the original on 2024-08-13. Retrieved 2024-08-13.
  6. ↑ "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors". clinicaltrials.gov. Archived from the original on 2024-08-13. Retrieved 2024-08-13.